A team led by Edison, Toner and Esvelt published a study demonstrating that assembling unregulated DNA fragments can circumvent current commercial DNA synthesis screening pipelines. The work, reported ahead of publication in Nature Communications, details experimental and computational approaches showing how fragment assembly and nonstandard submission pathways allow potentially hazardous sequences to evade automated screening filters used by many providers. Authors argue the finding exposes a regulatory and technical vulnerability in sequence‑screening regimes and call for revised policies and improved detection algorithms that account for fragment assembly and synthetic biology workflows. The paper proposes mitigation strategies including changes to synthesis provider practices and policy updates to close the gap. The research will feed ongoing government and industry debates on biosafety, dual‑use risk and the scope of sequence‑level governance for synthetic biology, potentially prompting both voluntary industry standards and regulatory action.